What insurance does a GLP-1 telehealth weight-loss company need?

A GLP-1 telehealth company is a virtual-care company with a specific, closely-watched clinical focus. Its core program is telemedicine professional liability for the clinicians who prescribe and cyber plus technology E&O for the platform and the patient data - typically structured across a physician-owned professional corporation (the PC) and a management-services organization (the MSO). What makes it distinct is the GLP-1 prescribing, which underwriters treat as a higher-scrutiny exposure.

Telemedicine professional liability for the PC: entity-level malpractice covering the practice's vicarious liability for its prescribing clinicians, rated on patient volume or revenue rather than a fixed physician roster.

Cyber and technology E&O for the MSO: coverage for the platform, the electronic health record, and the protected health information the company holds under HIPAA.

General liability, workers compensation, and directors-and-officers round out the program as the company operates and takes on capital.

Weight-management telehealth that prescribes GLP-1 medications (semaglutide, tirzepatide) is a high-scrutiny class right now. The regulatory environment around these drugs and around compounded versions, together with an active litigation climate, means fewer markets will write the professional liability, and those that do underwrite it closely. Disclosing the GLP-1 prescribing early is the practical approach, because a market that writes general telehealth may still decline the GLP-1 angle, and it is better to learn that at the start than at the end.

Whether the medication is branded or compounded matters to underwriters, as does the clinical protocol and the states of operation.

Many GLP-1 telehealth companies do not handle or dispense the medication themselves - the clinicians prescribe, and partner pharmacies fulfill and ship. When that is the case, the products liability and pharmacy exposure sits with the fulfillment pharmacies, and the telehealth company's program can be scoped to the clinical (professional liability) and platform (cyber and technology E&O) lines. A company that does dispense or that takes title to the medication carries a materially broader products and pharmacy exposure and needs a correspondingly broader program.

Because a GLP-1 telehealth risk combines telemedicine malpractice, technology, and cyber, some specialty virtual-care programs will write medical malpractice, technology E&O, and cyber within a single policy, while other placements split the clinical and platform lines across separate markets. Given the GLP-1 scrutiny, working the placement through specialty and surplus-lines markets that understand virtual care is usually the path, and disclosing the full clinical scope up front keeps it moving.